Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Buy Rating and 120 Price Target for Viking Therapeutics

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Maxim Group analyst Naz Rahman has once again expressed optimism in Viking Therapeutics (NASDAQ: VKTX), reiterating a Buy rating and setting a price target of $120.

This reaffirmation underscores the analyst’s ongoing bullish perspective on the company’s performance, signaling a strong belief in its future growth potential.

With this vote of confidence, investors may find reassurance in the stock’s trajectory as of March 15, 2024.

VKTX Stock Performance Declines Slightly on March 15, 2024: Market Analysis and Recommendations

On March 15, 2024, VKTX stock experienced a slight decline in its performance. The stock opened at $66.12, which was $1.07 higher than its previous close. Throughout the trading day, the price of VKTX shares dropped by $1.35, resulting in a 2.08% decrease from the market’s last close. Despite this drop, VKTX is still trading in the middle of its 52-week range and above its 200-day simple moving average. Fluctuations in stock prices are common and can be influenced by a variety of factors, including market conditions, company performance, and investor sentiment. It is recommended that investors conduct thorough research and consult with financial advisors before making any investment decisions.

VKTX Stock Performance: Net Income and EPS Fluctuations on March 15, 2024

On March 15, 2024, VKTX stock experienced mixed performances based on the available financial data. The company’s net income for the past year was reported at -$85.89 million, showing a decrease of 24.73% compared to the previous year. In the last quarter, VKTX’s net income was -$24.61 million, reflecting a 9.19% decrease from the previous quarter.

Earnings per share (EPS) for VKTX were reported at -$0.91 for the past year, indicating a 1.57% increase from the previous year. However, in the last quarter, EPS was recorded at -$0.25, reflecting an 8.91% decrease from the previous quarter.

Investors and analysts closely monitor a company’s financial metrics, such as net income and EPS, to evaluate its profitability and potential for future growth. The fluctuations in VKTX’s net income and EPS over the past year and quarter suggest some volatility in the company’s financial performance.

Overall, VKTX stock performances on March 15, 2024, were influenced by a mix of factors, including changes in net income and EPS. Investors should continue to monitor VKTX’s financial data and market trends to make informed decisions about their investment in the company.

Tags: VKTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

FAT Brands Inc Poised for Rapid Growth and Expansion

Technology Artificial intelligence Markets and money

MicroStrategys Stock Falls After Announcing Convertible Senior Notes Offering for Bitcoin Acquisition

Biotechnology Markets and money

SELLAS Life Sciences Group Faces Stock Decline After Announcing Registered Direct Offering and Private Placement

Recommended

Transportation Stock Bull Market

JR Kyushu Implements AIPowered AMD Kria K26 SOM for Enhanced Track Inspection Efficiency and Safety

2 years ago
TMUS stock news

Wedbush Analyst Maintains Outperform Rating and Raises Price Target for Global Payments

2 years ago
JD.com Stock

JD.com Shares Surge on Robust Performance and Strategic Moves

3 months ago
Mobile-handsets

Palantir Technologies Reveals Revenue Projections for Q1 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Procter & Gamble Shares Approach a Critical Juncture

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

Palantir Shares: A Wall Street Divide and a Bold New Price Target

Nvidia Accelerates AI Dominance with Early Chip Launch and Strategic Expansions

Netflix Shares Under Pressure Amid High-Stakes Acquisition Battle

Marvell Technology Shares Face Conflicting Market Cues

Trending

Viking Therapeutics Stock
Analysis

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

by Felix Baarz
January 11, 2026
0

The shares of Viking Therapeutics, a biotechnology firm, are presenting investors with a conflicting narrative this week....

Astera Labs Stock

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

January 11, 2026
Realty Income Stock

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

January 11, 2026
Procter & Gamble Stock

Procter & Gamble Shares Approach a Critical Juncture

January 11, 2026
Vital Farms Stock

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: A Tale of Clinical Progress and Insider Selling
  • Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals
  • Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com